Status: Not yet recruiting
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chongbo ZhaoUpdated: Jan 6, 2025Locations: 1
Eligibility criteria
Subjects or their legal representative voluntary signing the ICF, and willing an... [+15]
Subjects have a history of severe hypersensitivity or allergy; [+27]